upsarin c
upsa sas - acetilsalicilo rūgštis/askorbo rūgštis - šnypščiosios tabletės - 330 mg/200 mg - acetylsalicylic acid, comb. excl. psycholeptics
alka-prim
pharmaceutical works polpharma s.a. - acetilsalicilo rūgštis - šnypščiosios tabletės - 330 mg - acetylsalicylic acid
alka-seltzer
bayer, uab - acetilsalicilo rūgštis - šnypščiosios tabletės - 324 mg - acetylsalicylic acid
cephyl
boiron - acetilsalicilo rūgštis/kofeinas/Šunvyšnių (atropa bella-donna) tinktūra/Įvairiaspalvių vilkdalgių (iris versicolor) tinktūra/nuodingųjų činčiberų (strychnos nux-vomica) tinktūra/nuodingųjų spigelijų (spigelia anthelmia) tinktūra/geltonžiedžių kumpotrių (gelsemium sempervirens) tinktūra - tabletės - 330 mg/36,6 mg/0,004 µg/0,004 µg/0,004 µg/0,004 µg/0,004 µg - acetylsalicylic acid, comb. excl. psycholeptics
cardiopirin
pharmaswiss, uab - acetilsalicilo rūgštis - skrandyje neirios tabletės - 75 mg - acetylsalicylic acid
aspirin-c
limedika, uab - acetilsalicilo rūgštis/askorbo rūgštis - šnypščiosios tabletės - 400 mg/240 mg - acetylsalicylic acid
agranin
ibe pharma, uab - acetilsalicilo rūgštis/paracetamolis/kofeinas - tabletės - 250 mg/250 mg/65 mg - acetylsalicylic acid, comb. with psycholeptics
rivaroxaban viatris (previously rivaroxaban mylan)
mylan ireland limited - rivaroksabanas - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitromboziniai vaistai - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers. rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery. treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.
aggrenox
boehringer ingelheim international gmbh - dipiridamolis/acetilsalicilo rūgštis - modifikuoto atpalaidavimo kietosios kapsulės - 200 mg/25 mg - combinations
citramon phs
corpus medica, uab - acetilsalicilo rūgštis/paracetamolis/kofeinas - tabletės - 240 mg/180 mg/30 mg - salicylic acid and derivatives